Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Merck (MRK) ended the recent trading session at $80.93, demonstrating a -1.77% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.83%. At the same time, ...

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The stock's fall snapped a four-day winning streak.

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

Get the detailed quarterly/annual income statement for Merck & Co., Inc. (MRK). Find out the revenue, expenses and profit or loss over the last fiscal year.